...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
AGORACOM NEWS FLASH

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Message: OncLive article mentioning ZEN-3694

Nice article about epigenetics in cancer research.  Article mentions some of the competitors in trials, including Gilead, Incyte, GSK, AbbVie and Zenith and the tumor types they are targeting.   This whole topic of epigenetic mechanisms is gaining more and more credibility as top researchers and companies keep finding new and interesting results.

It seems that thrombocytopenia (low blood platelet count) occurs at different dosing levels with many of these in Phase I/II trials.

Zenith is mentioned as being in I/II trial with enzalutamide but not much more info. 

You may need to register (free) to view the entire article. 

https://www.onclive.com/publications/oncology-live/2018/vol-19-no-12/bet-inhibitors-form-a-growing-area-of-epigenetic-cancer-research 

masila

Share
New Message
Please login to post a reply